Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India

Drug Profile

Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India

Alternative Names: Adalimumab biosimilar - Neuclone/Serum Institute of India; Denosumab biosimilar - Neuclone/Serum Institute of India; Palivizumab biosimilar - Neuclone/Serum Institute of India; Trastuzumab biosimilar - Neuclone/Serum Institute of India; Ustekinumab biosimilar - Neuclone/Serum Institute of India

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuClone; Serum Institute of India
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators; Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors; RANK ligand inhibitors; Tumour necrosis factor alpha inhibitors; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 22 Mar 2016 Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India is available for licensing in Australia, Canada, Europe, Japan, New Zealand, Scandinavia, South Korea, Taiwan, USA, United Kingdom as of 22 Mar 2016. http://www.neuclone.com
  • 22 Mar 2016 Preclinical trials in Cancer in India, Australia (Parenteral)
  • 22 Mar 2016 Preclinical trials in Inflammation in India, Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top